Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
The last earnings update was 28 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Cellectar Biosciences. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Cellectar Biosciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
Cellectar Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Cellectar Biosciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Cellectar Biosciences's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Cellectar Biosciences's finances.
The net worth of a company is the difference between its assets and liabilities.
Cellectar Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Cellectar Biosciences's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Cellectar Biosciences's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Cellectar Biosciences has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. James V. Caruso, also known as Jim, has been the Chief Executive Officer and President of Cellectar Biosciences, Inc. since June 15, 2015. Mr. Caruso served as the Chief Commercial Officer and Executive Vice President of Allos Therapeutics Inc. from June 2006 to August 24, 2010. He served as Senior Vice President of Sales & Marketing at Bone Care International Inc. since June 2002 to May 2005 and served as Vice President, Sales from August 2002 to November 2003. He served as Head of Sales of Bone Care International Inc. since August 2002; Head of Marketing since August 2002 and Vice President- Sales from August 2002 to November 2003. He served as Executive Vice President, Chief Operating Officer since August 2010 until June 2015 and co-Founder of HIP Innovation Technology, LLC and serves as Director. He was Vice President of Sales of the Neuroscience Business Unit at Novartis from June 2001 to August 2002. He served as Vice President of Sales at BASF Pharmaceuticals from June 2000 to June 2001 and from 1988 to June 2000. He held several positions at Bristol Myers Squibb including Director of Sales- West Coast and Senior Director of Serzone Marketing. Mr. Caruso has a wide range of expertise in both drugs and devices, including a strong background in oncology. He has more than 25 years of industry experience. He has been a Director at Cellectar Biosciences, Inc. since June 15, 2015. Mr. Caruso earned his Bachelor of Science degree in Finance from the University of Nevada.
Jim's compensation has been consistent with company performance over the past year, both up more than 20%.
Jim's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Cellectar Biosciences management team is less than 2 years, this suggests a new team.
Chief Business Officer
VP & CFO
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Cellectar Biosciences board of directors is about average.
Board of Directors
Independent Chairman of the Board
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.